Tag: Astrazeneca
AstraZeneca: Auriane Cano-Chancel as head of oncology
(CercleFinance.com) – AstraZeneca announces the appointment of Auriane Cano-Chancel as Head of Oncology at AstraZeneca France. She replaces Dana Vigier, appointed Global Commercial Vice-President of the Lynparza Franchise & DDR…
AstraZeneca: stopping a cholesterol-lowering program with Ionis
(CercleFinance.com) – Ionis Pharmaceuticals announced on Friday that AstraZeneca had decided not to pursue the development of the PCSK9 program in hypercholesterolemia following phase 2b results deemed mixed. In a…
AstraZeneca: Positive data on three cancer drugs
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
AstraZeneca: positive data on three cancer drugs
(CercleFinance.com) – AstraZeneca presented positive data on its three main cancer drugs on Sunday at the European Society for Medical Oncology (ESMO) congress, which is currently being held in Paris.…
AstraZeneca: Favorable data in ovarian cancer
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
AstraZeneca: sharp decline after an analyst downgrade
(CercleFinance.com) – AstraZeneca shares were attacked on the London Stock Exchange on Wednesday in the wake of a downgrade by Morgan Stanley analysts, who went from ‘overweight’ to ‘online weight’…
AstraZeneca: positive phase 3 results with Ionis
(CercleFinance.com) – Ionis Pharmaceuticals announced on Wednesday that eplontersen, the treatment for familial amyloid polyneuropathy it is developing with AstraZeneca, has met its primary endpoint in phase 3 clinical trials.…
AstraZeneca: Net decline after an analyst downgrade
(CercleFinance.com) – AstraZeneca shares were attacked on the London Stock Exchange on Wednesday in the wake of a downgrade by Morgan Stanley analysts, who went from ‘overweight’ to ‘online weight’…
AstraZeneca: Forxiga approved in China
(CercleFinance.com) – AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in China to reduce the risk of sustained decreases in estimated glomerular filtration rate, renal failure…
AstraZeneca: anti-Covid Evusheld approved in Japan
(CercleFinance.com) – AstraZeneca announced on Tuesday the approval in Japan of Evusheld for both the prevention and treatment of severe forms of Covid-19 in the most vulnerable people. The biopharmaceutical…
AstraZeneca: New data on heart failure
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
AstraZeneca: Japan authorizes three drugs
AstraZeneca announced Thursday that the Japanese Ministry of Health has officially approved the use of Lynparza in the treatment of early breast cancer and Tagrisso in lung cancer. The biopharmaceutical…